3 Teams Developing Coronavirus Vaccines Report Promising Results From Phase II Studies

New York Times: Three Coronavirus Vaccine Developers Report Promising Initial Results
“The race for a vaccine against the coronavirus intensified on Monday as three competing laboratories released promising results from early trials in humans. Now comes the hard part: proving that any of the vaccines protects against the virus, and establishing how much immunity they provide — and for how long. … Two of the vaccine developers — the first, a partnership between Oxford University and the British-Swedish drug maker AstraZeneca; the second, the Chinese company CanSino Biologics — published their early results as peer-reviewed studies in The Lancet, a British medical journal. A joint venture between the drug giant Pfizer and the German company BioNTech shared results online before peer review, and invited comparisons to the biotech company Moderna, which uses a similar technology and released early results last week. All the developers that released results on Monday said their vaccines had produced strong immune responses with only minor side effects…” (Kirkpatrick, 7/20).

Additional coverage of the vaccine trials’ results is available from AP, Axios, Bloomberg, CNBC, The Guardian, POLITICO, Reuters (2), STAT, TIME, USA TODAY, VOA News, Wall Street Journal, and Washington Post.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.